Loading
Led SWOG 1500, the first randomised trial to set a standard for papillary kidney cancer, and studies of the microbiome in RCC immunotherapy.
Sumanta Pal was principal investigator of SWOG PAPMET (S1500), which showed cabozantinib outperforms sunitinib in metastatic papillary renal cell carcinoma, the first practice-changing randomised trial in a non-clear-cell histology, and a lead investigator of COSMIC-313 and CONTACT-03. He led the randomised trial of the live bacterial product CBM588 with immunotherapy. He co-directs the kidney cancer programme at City of Hope.
Shares CONTACT-03, Atezolizumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Small-molecule kinase inhibitors and the tag rcc.
Shares Ipilimumab, Nivolumab, Immune checkpoint inhibitors and the tag microbiome.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors and the tag rcc.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Atezolizumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Small-molecule kinase inhibitors.